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Rothmund-Thomson syndrome (RTS) is an autosomal recessive disorder caused by deleterious mutations in the
RECQL4 gene on chromosome 8. The RECQL4 gene structure is unusual because it contains many small introns
!100 bp. We describe a proband with RTS who has a novel 11-bp intronic deletion, and we show that this mutation
results in a 66-bp intron too small for proper splicing. Constraint on intron size may represent a general mutational
mechanism, since human-genome analysis reveals that ∼15% of genes have introns !100 bp and are therefore
susceptible to size constraint. Thus, monitoring of intron size may allow detection of mutations missed by exon-
by-exon approaches.
Rothmund-Thomson syndrome (RTS [MIM #268400])
is an autosomal recessive disorder characterized by a
poikilodermatous rash, skeletal anomalies, small stat-
ure, alopecia, cataracts, and strong predisposition to
malignancy, particularly osteosarcoma (Vennos et al.
1992; Wang et al. 2001). Truncating mutations in the
RECQL4 gene (MIM #603780) have been previously
reported in four kindreds with RTS (Kitao et al. 1999b;
Lindor et al. 2000; Wang et al. 2000).
The RECQL4 gene structure is unusual because it
contains 21 exons in only 6 kb of genomic DNA se-
quence (Kitao et al. 1999a). Unlike most human genes,
which have large introns, RECQL4 has 13 introns that
are !100 bp in length (fig. 1A). Introns less than ∼80
bp have been shown to splice inefficiently in model sys-
tems, despite the presence of consensus splice-donor and
-acceptor sites and branch-point sites (van Santen and
Spritz 1985; Berget 1995).
One of our probands with RTS (individual FCP-102),
who had osteosarcoma and was from a consanguineous
Mexican family, was found to be homozygous for an 11-
bp deletion (g2746del11) in intron 8 (fig. 1B). A 10-bp
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direct repeat flanks the deleted bases. This intronic de-
letion was not found in 100 population control subjects,
including 33 Hispanic control subjects, and sequencing
of the RECQL4 coding region in FCP-102 revealed no
other truncating mutations. The deletion (intronic base-
pair position 25–35) reduced the 77-bp intron to 66 bp
in length, leaving the 3′ and 5′ consensus splice sites intact.
Within the deleted sequence there is a potential branch-
point site (44 bp upstream of the 3′ splice site) with a
partial match to the YNYURAY branch-point consensus
sequence (Li and Pritchard 2000). However, 20 bp down-
stream, in a region of the intron not affected by the de-
letion, there is another sequence, with a perfect match to
the branch-point consensus sequence. The deleted se-
quence (GCTGGGCTGAG) does contain a sequence that
matches the consensus G2(X1-4)G3 for an intronic splic-
ing enhancer (ISE) (McCarthy and Phillips 1998).
We hypothesized that this deletion represents the dis-
ease-causing mutation because it reduces the intron to
a size incompatible with proper splicing. RT-PCR using
primers within exons 5 and 11 would be expected to
yield a product of 791 bp, as was seen in analysis of a
wild-type control sample (fig. 2A). In contrast, RT-PCR
of RNA from lymphoblasts and fibroblasts of FCP-102
demonstrated a predominant, larger aberrant product,
of 857 bp. The proband’s mother is heterozygous for
the deletion and has both the expected 791-bp RT-PCR
product and the aberrant product. Cloning and sequenc-
ing of the major RT-PCR product in FCP-102 showed
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Figure 1 Intronic deletion in a proband with RTS. A, Schematic diagram of RECQL4 gene (adapted from Kitao et al. 1999a). The
helicase region is unshaded. Asterisks indicate introns !100 bp. B, Sequence of intron 8, showing 11-bp deletion in FCP-102 (boxed), potential
branch points (dotted line), and potential intronic splicing enhancer (underline). The sequence used to create the “replaced construct” is shown
above the deletion.
retention of intron 8 containing the 11-bp deletion.
Analysis of other cloned RT-PCR products from FCP-
102 revealed a 750-bp product that retained intron 8
but that utilized a cryptic 5′ splice site in exon 9. Both
of these RNA species are predicted to generate a pre-
mature stop codon. The major RT-PCR product from
wild-type RNA showed proper splicing of intron 8. Ad-
ditional bands resulting from misspliced products were
also seen in analysis of RNA from wild-type control
subjects and were found to retain intron 8. However,
these were not the predominant bands, and, conversely,
multiple RT-PCRs performed with FCP-102 RNA never
demonstrated proper splicing of intron 8.
To test if intronic size constraint could be responsible
for this missplicing, we subcloned exons 5–10, fromwild-
type and FCP-102 genomic DNA, into a mammalian ex-
pression vector (pCDNA3.1/V5-His-TOPO; Invitrogen).
Murine NIH3T3 cells were transiently transfected with
the constructs. RNA was isolated from cytoplasmic ly-
sates, and DNAse I was treated to minimize contamina-
tion by unprocessed transcripts and transfectedDNA.RT-
PCR using primers specific for the human gene revealed
bands representing the proper splicing of intron 8 in RNA
from the construct with the wild-type sequence and rep-
resenting aberrant splicing of intron 8 in RNA from the
FCP-102 construct, recapitulating the pattern seen above
for the endogenous genes (fig. 2B). We then used site-
directed mutagenesis to restore a normal-size intron, by
replacing the 11-bp deletion (GCTGGGCTGAG) with an
unrelated sequence (TAGATATCATA). The replaced se-
quence does not contain the consensus for either a branch-
point site or an intronic splicing enhancer (Li and Prit-
chard 2000; McCarthy and Phillips 1998). Transfection
and RT-PCR demonstrated restoration of splicing across
intron 8 in RNA derived from the replaced 11-bp con-
struct (fig. 2B). Correction of the missplicing defect sug-
gests that intronic size constraint is a mutational mech-
anism leading to the RTS phenotype in this patient. The
ratio of RT-PCR products as shown in figure 2B was
observed to remain in the linear range, in 18–30 cycles
of PCR (data not shown). The relative amount of correctly
spliced product is less in the replaced construct than in
the wild type. This may be due to loss of the ISE sequence
found in the deleted sequence. However, the fact that
correct splicing of intron 8 occurs in the replacedconstruct
when length is restored without recreating an ISE argues
that size constraint contributes to the missplicing defect
in this patient.
The higher-molecular-weight bands seen in RT-PCR
from all three transfectants are misspliced products (that
retain introns), as was seen in analysis of endogenous
RNA described above. Missplicing of a proportion of
wild-type templates presumably occurs because the small
introns in RECQL4 are inefficiently spliced.
Our results illustrate that deletions in small introns can
be deleterious, because of a constraint on intron size. This
has been previously suggested in one case of adult poly-
cystic kidney disease (Peral et al. 1995). These results
contrast with a recently reported large intronic deletion
in WNKI, which results in increased expression of the
protein in pseudohyperaldosteronism type II (Wilson et
al. 2001). However, in this case, the resulting intron re-
mains several hundred base pairs in length. Intronic de-
letions in small introns are likely to be important for other
disease genes as well. Analysis of the April 2001 version
of the Human Genome Assembly (Lander et al. 2001;
also see the UCSCHumanGenome ProjectWorkingDraft
Web site) reveals that 15% of unique mRNAs have at
least one intron that is !100 bp. Of these genes with small
introns, 48% are located in finished sequence, demon-
strating that this is not an artifact of the genomic draft
assembly. Thus, full mutational analysis should include
Reports 167
Figure 2 RT-PCR showing both splicing error due to intronic
deletion and correction of defect by restoration of intron size. A, RT-
PCR of lymphoblast RNA from proband FCP-102, his mother, and
normal control. Primers are within exons 5 and 11 (between the white
arrows in fig. 1A). The normal product is expected to be 791 bp. The
aberrant larger product is 857 bp. B, RT-PCR of transcripts from
NIH3T3 cells transfected with expression constructs containing exons
5–10 of RECQL4 from wild type, FCP-102, or wild type replaced
with 11 unrelated base pairs at the deletion site. Primers are within
exons 7 and 9 (between the black arrows in fig. 1A). Predicted sizes
are 240 bp, for correct splicing of intron 8; 306 bp, for retention of
intron 8 containing the deletion; and 317 bp, for the retention of wild-
type intron 8. The highest band in each lane represents retention of
introns 7 and 8 (389 bp for FCP-102 and 400 bp for wild type and
the replaced construct).
assay for deletions in small introns, which, otherwise,may
be missed in an exon-by-exon approach that surveys only
intron/exon boundaries.
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